| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H44O2 |
| Molecular Weight | 400.6371 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C
InChI
InChIKey=ZPACYDRSPFRDHO-ROBAGEODSA-N
InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+
| Molecular Formula | C27H44O2 |
| Molecular Weight | 400.6371 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 3 |
| Optical Activity | NONE |
Gefarnate is a drug used for the treatment of gastric ulcers. It also has been proposed for use in the treatment of dry eye syndrome, although for this disease it was discontinued in 2008. The mechanism of action consists of the normalisation of the mucous secretion, followed by the restoration of the normal defensive mucous barrier.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
For the studies in vitro, cultured rat cornea sections (3 mm diameter) were incubated with radiolabeled sodium sulfate, rinsed, and then incubated for 30 min in the presence of the drug. Gefarnate significantly increased the mucin-like glycoprotein secretion from cultured rat corneas
